MDWD MediWound Ltd.
$14.20+6.05%
Last close: · regular session · Last 60 sessions
MDWD dilution and offerings
Offering filing 424B5 in Nov 2026: it registers shares for sale.
- Float
- 9.6M
- Last offering
- 424B5 · Nov 2026
- Last filing
- FWP · Nov 3, 2026
Latest SEC filings for MDWD
| FWP | ||
| 424B5 | Offering — dilutive | |
| 6-K | Foreign issuer report | |
| 6-K | Foreign issuer report | |
| SCHEDULE 13G | ||
| 6-K | Foreign issuer report | |
| 6-K | Foreign issuer report | |
| 6-K | Foreign issuer report | |
| 20-F | Annual report | |
| S-8 | Employee stock plan |
Dilution today: new offering filings and reverse splits
Recent offering filing (424B5, Nov 2026). Float: 9.6M shares. Latest SEC filing: FWP on Nov 3, 2026. MDWD closed at $14.20 (+6.05%) on Nov 4, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for MDWD in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
- Exchange: NASDAQ
- Employees: 111
- Website: https://www.mediwound.com
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Latest MDWD news
- MediWound announces $15M public offering of ordinary shares Read article
Recent dilution filers
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.